Monitoring method for neuromuscular disease biological medicine

Abstract

The invention provides a biological medicine monitoring method for neuromuscular diseases, and relates to the field of medicine monitoring methods. The monitoring method for the neuromuscular disease biological medicine comprises the following steps: S1, injecting a medicine with a standard concentration into a patient, and recording the injection time, S2, extracting blood and urine of the patient, S3, dividing the blood and the urine into three groups which are samples extracted in three time periods, monitoring parameters of the three groups of samples, and determining the concentration of the medicine according to the parameters of the three groups of samples. And S4, comparing the three groups of parameters, and analyzing a monitoring result. A blood sample and a urine sample are respectively sampled in three time periods, different parameters in the three time periods are monitored, the optimal taking time of a therapeutic drug is judged, the therapeutic effect of neuromuscular diseases is improved, analysis is carried out in a graph mode, and a comparison result is more clearly seen.

Description

Technical Field

[0001] The present invention relates to the field of medicine monitoring methods, in particular to a monitoring method for neuromuscular disease biomedicine. Background Art

[0002] Neuromuscular disease is a group of diseases that involve the nerves and muscles. There are many types of neuromuscular disease. Neuromuscular disease is not a single disease, but a general term for a large group of diseases.

[0003] When treating neuromuscular diseases, drugs are needed. Before using the drugs, the drugs need to be monitored to monitor the patient's recovery. When using the drugs, it is not clear in which time period the drugs will achieve the best therapeutic effect for the patient. If the patient uses the drugs directly, the treatment effect will be unstable. Summary of the invention

[0004] Technical issues solved

[0005] In view of the shortcomings of the prior art, the present invention provides a monitoring method for biomedicine for neuromuscular disease, which solves the problem of unclear optimal time period for taking drugs.

[0006] Technical Solution

[0007] To achieve the above objectives, the present invention is implemented through the following technical solutions: A monitoring method for neuromuscular disease biomedicine, comprising the following steps:

[0008] S1. Inject the drug of standard concentration into the patient and record the injection time;

[0009] S2. Draw blood and urine from the patient;

[0010] S3, dividing the blood and urine into three groups, the three groups are samples extracted in three time periods respectively, and monitoring the parameters of the three groups of samples;

[0011] S4. Compare the three groups of parameters and analyze the monitoring results.

[0012] Preferably, the three groups of samples are blood samples and urine samples, respectively. The parameters that need to be monitored in the blood samples include serum creatine phosphokinase (CPK), serum myoglobin (MB), and serum pyruvase (PK), and the parameters that need to be monitored in the urine samples include glucose (GLU) and bilirubin (BI L).

[0013] Preferably, the normal content ranges of serum creatine phosphokinase (CPK), serum myoglobin (MB), and serum pyruvase (PK) are: serum creatine phosphokinase (CPK) 18-198u / l, serum myoglobin (MB) 8-20μg / l, and serum pyruvase (PK) 84.30u / l.

[0014] Preferably, when analyzing the parameters in S3, the urine sample monitoring judgment formula is Y=a*b, wherein a represents the judgment result of the glucose (GLU) content, and b represents the judgment result of the bilirubin (BI L) content. When the judgment result is monitored as positive, the output result is 0, otherwise it is 1. The data Y output result of 0 indicates that the glucose (GLU) and bilirubin (BI L) in the patient's urine during this time period are positive, which is an abnormal phenomenon, otherwise it is a normal phenomenon.

[0015] Preferably, the parameter comparison in S4 is to make a blood parameter comparison chart and a urine parameter comparison chart for three time periods, and the blood parameter comparison chart is vertically divided into the time axis and horizontally divided into the content of serum creatine phosphokinase (CPK), serum myoglobin (MB), and serum pyruvase (PK), and the urine parameter comparison chart is vertically divided into the time axis and horizontally divided into glucose (GLU) and bilirubin (BI L).

[0016] Preferably, the three time periods are 8:00-9:30 in the morning, 11:30-13:00 in the afternoon, and 18:00-19:30 in the evening, and the blood and urine samples are drawn 1 hour after taking the samples.

[0017] Preferably, the blood and urine samples are placed in test tubes, and the corresponding extraction time period, parameters to be monitored, and names of therapeutic drugs to be taken are labeled on the test tubes.

[0018] Beneficial Effects

[0019] The present invention provides a monitoring method for neuromuscular disease biomedicine. It has the following beneficial effects:

[0020] By sampling blood and urine samples in three time periods, different parameters of the three time periods are monitored to determine the best time to take therapeutic drugs, increase the therapeutic effect of neuromuscular diseases, and analyze them in the form of graphs to see the comparison results more clearly. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 It is a flow chart of the present invention. DETAILED DESCRIPTION

[0022] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0023] Embodiment 1:

[0024] like Figure 1 As shown, an embodiment of the present invention provides a monitoring method for neuromuscular disease biomedicine, comprising the following steps:

[0025] S1. Inject the drug of standard concentration into the patient and record the injection time;

[0026] S2. Draw blood and urine from the patient;

[0027] S3, blood and urine are divided into three groups, the three groups are samples extracted in three time periods, and the parameters of the three groups of samples are monitored. The three groups of samples are blood samples and urine samples. The parameters that need to be monitored in the blood sample are serum creatine phosphokinase (CPK), serum myoglobin (MB), serum pyruvase (PK), and the parameters that need to be monitored in the urine sample are glucose (GLU) and bilirubin (BI L). When the parameters are analyzed in S3, the urine sample monitoring judgment formula is Y=a*b, where a represents the glucose (GLU) content judgment result, and b represents the bilirubin (BIL) content judgment result. When the judgment result is positive, the output result is 0, otherwise it is 1. The data Y output result is 0, which means that the glucose (GLU) and bilirubin (BI L) content of the patient's urine in this time period are positive. L) is positive, which is an abnormal phenomenon, otherwise it is a normal phenomenon. The three time periods are 8:00-9:30 in the morning, 11:30-13:00 in the afternoon, and 18:00-19:30 in the evening. The blood and urine samples are drawn 1 hour after taking the samples. The Y judgment result is 0, which means that the time period is not suitable for taking the medicine, otherwise the medicine can continue to be taken.

[0028] S4. Compare the three groups of parameters and analyze the monitoring results. Compare the parameters in S4, make blood parameter comparison charts and urine parameter comparison charts for the three time periods, and use the blood parameter comparison chart as the time axis vertically and serum creatine phosphokinase (CPK), serum myoglobin (MB), and serum pyruvase (PK) content horizontally. The urine parameter comparison chart has a time axis vertically and glucose (GLU) and bilirubin (BIL) horizontally. Through the comparison chart, it can be clearly seen which time period has a better treatment effect. By setting the normal standard value and comparing it with the monitored parameters, the larger the comparison result, the weaker the treatment effect, and vice versa.

[0029] The normal range of serum creatine phosphokinase (CPK), serum myoglobin (MB), and serum pyruvase (PK) is: serum creatine phosphokinase (CPK) 18u / l, serum myoglobin (MB) 8μg / l, serum pyruvase (PK) 84.30u / l, which is the normal value for males.

[0030] Blood and urine samples are placed in test tubes, and the corresponding extraction time period, parameters to be monitored, and names of therapeutic drugs taken are labeled on the test tubes to facilitate staff to make comparison charts.

[0031] Embodiment 2:

[0032] like Figure 1 As shown, an embodiment of the present invention provides a monitoring method for neuromuscular disease biomedicine, comprising the following steps:

[0033] S1. Inject the drug of standard concentration into the patient and record the injection time;

[0034] S2. Draw blood and urine from the patient;

[0035] S3, blood and urine are divided into three groups, and the three groups are samples extracted in three time periods respectively, and the parameters of the three groups of samples are monitored. The three groups of samples are blood samples and urine samples respectively. The parameters that need to be monitored in the blood sample are serum creatine phosphokinase (CPK), serum myoglobin (MB), serum pyruvase (PK), and the parameters that need to be monitored in the urine sample are glucose (GLU) and bilirubin (BIL). When analyzing the parameters in S3, the urine sample monitoring judgment formula is Y=a*b, where a represents the judgment result of the glucose (GLU) content, and b represents the content of glucose (GLU). It indicates the judgment result of bilirubin (BIL) content. When the judgment result is positive, the output result is 0, otherwise it is 1. The data Y output result is 0, which means that the glucose (GLU) and bilirubin (BIL) in the patient's urine during this period are positive, which is an abnormal phenomenon. Otherwise it is a normal phenomenon. The three time periods are 8:00-9:30 in the morning, 11:30-13:00 in the afternoon, and 18:00-19:30 in the evening. The blood and urine samples are drawn 1 hour after taking the samples. The Y judgment result is 0, which means that the time period is not suitable for taking the medicine, otherwise the medicine can continue to be taken.

[0036] S4. Compare the three groups of parameters and analyze the monitoring results. Compare the parameters in S4, make blood parameter comparison charts and urine parameter comparison charts for the three time periods, and use the blood parameter comparison chart as the time axis vertically and serum creatine phosphokinase (CPK), serum myoglobin (MB), and serum pyruvase (PK) content horizontally. The urine parameter comparison chart has a time axis vertically and glucose (GLU) and bilirubin (BI L) horizontally. Through the comparison chart, it can be clearly seen which time period has a better treatment effect. By setting the normal standard value and comparing it with the monitored parameters, the larger the comparison result, the weaker the treatment effect, and vice versa.

[0037] The normal range of serum creatine phosphokinase (CPK), serum myoglobin (MB), and serum pyruvase (PK) is: serum creatine phosphokinase (CPK) 198u / l, serum myoglobin (MB) 20μg / l, serum pyruvase (PK) 84.30u / l, which is the normal value for males.

[0038] Blood and urine samples are placed in test tubes, and the corresponding extraction time period, parameters to be monitored, and names of therapeutic drugs taken are labeled on the test tubes to facilitate staff to make comparison charts.

[0039] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A method for monitoring biomedicine for neuromuscular disease, characterized in that: The following steps are involved: S1. Inject the drug of standard concentration into the patient and record the injection time; S2. Draw blood and urine from the patient; S3, dividing the blood and urine into three groups, the three groups are samples extracted in three time periods respectively, and monitoring the parameters of the three groups of samples; S4. Compare the three groups of parameters and analyze the monitoring results.

2. A method for monitoring biomedicine for neuromuscular disease according to claim 1, characterized in that: The three groups of samples are blood samples and urine samples. The parameters that need to be monitored in the blood samples include serum creatine phosphokinase (CPK), serum myoglobin (MB), and serum pyruvase (PK). The parameters that need to be monitored in the urine samples include glucose (GLU) and bilirubin (BIL).

3. A method for monitoring biomedicine for neuromuscular disease according to claim 2, characterized in that: The normal content ranges of serum creatine phosphokinase (CPK), serum myoglobin (MB), and serum pyruvase (PK) are: serum creatine phosphokinase (CPK) 18-198u / l, serum myoglobin (MB) 8-20μg / l, and serum pyruvase (PK) 84.30u / l.

4. A method for monitoring biomedicine for neuromuscular disease according to claim 2, characterized in that: When analyzing the parameters in S3, the urine sample monitoring judgment formula is Y=a*b, wherein a represents the judgment result of the glucose (GLU) content, and b represents the judgment result of the bilirubin (BIL) content. When the judgment result is monitored as positive, the output result is 0, otherwise it is 1. The data Y output result of 0 indicates that the glucose (GLU) and bilirubin (BIL) in the patient's urine during this time period are positive, which is an abnormal phenomenon, otherwise it is a normal phenomenon.

5. A method for monitoring biomedicine for neuromuscular disease according to claim 1, characterized in that: The parameters in S4 are compared to make blood parameter comparison graphs and urine parameter comparison graphs for three time periods, and the blood parameter comparison graph is vertically divided into the time axis and horizontally divided into the contents of serum creatine phosphokinase (CPK), serum myoglobin (MB), and serum pyruvase (PK). The urine parameter comparison graph is vertically divided into the time axis and horizontally divided into glucose (GLU) and bilirubin (BIL).

6. A method for monitoring biomedicine for neuromuscular disease according to claim 1, characterized in that: The three time periods are 8:00-9:30 in the morning, 11:30-13:00 in the afternoon, and 18:00-19:30 in the evening, and blood and urine samples are drawn 1 hour after taking the samples.

7. A method for monitoring biomedicine for neuromuscular disease according to claim 1, characterized in that: The blood and urine samples are placed in test tubes, and the corresponding extraction time period, the parameters to be monitored, and the name of the therapeutic drug to be taken are labeled on the test tubes.

Images